Net Revenues Equal to Prior Year and Net Losses Narrowed Compared to Prior
IRVINE, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologists for tissue and tumor ablation, today reported that despite flat year-over-year revenue, net losses narrowed year-over-year on higher gross margin during the second quarter ended June 30, 2008.
Total revenues for the second quarter of 2008 were $7.9 million, equal
to the second quarter of 2007. Domestic probe sales, as well as the
estimated number of domestic cryoablation procedures performed, in the
second quarter and the first six months of 2008 and 2007 are summarized in
the following table:
Three Months Ended Six Months Ended
June 30, June 30,
2008 2007 2008 2007
Estimated domestic cryoablation
procedures 2,292 2,435 4,860 4,750
Number of cryoprobes sold:
Straight probes 9,074 10,131 19,357 19,895
Right-angle probes 2,054 1,626 3,974 3,073
Total 11,128 11,757 23,331 22,968
Probe sales are reported in two categories: straight probes, which are typically, although not always, used in prostate procedures and right-angle probes, which are typically used in procedures other than prostate procedures.
Gross margin in the second quarter of
|SOURCE Endocare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved